CLINICAL USE OF DIURECTICS IN CHF, NEPHROTIC SYNDROME: A REVIEW

[1]PRODIP ROY, [1]KRISHANU PRAMANICK, [1]SUMAN KHAN, [1]NILADRI GHOSAL, [2]VISHAL GOVIND SAKHARE, [3]MUJEEB MAHAMADHUSEN SHAIKH, [4]SUBHASISH DUTTA, [5]DEBTIRTHA MAITY

[1]Department of Pharmacology, Netaji Subhas Chandra Bose Institute of Pharmacy, Chakdaha, Nadia, West Bengal, India

[1]Department of Pharmaceutics, Netaji Subhas Chandra Bose Institute of Pharmacy, Chakdaha, Nadia, West Bengal, India

[2]Assistant Professor SBSPMS B. Pharmacy College Ambajogai Maharashtra

[3]Pharmaceutical Quality Assurance, M.c.e. Society's Allana college of pharmacy Azam Camp Pune

[4]Faculty of Pharmacology M.R college of Pharmaceutical Science and research West Bengal India

[5]Department of Pharmacy, Eminent College of Pharmaceutical Technology, Barasat, Kolkata (W.B.) - India

ABSTRACT

Diuretics, in one form or another, have been around for centuries and this review sets out to chart their development and clinical use. Starting with the physiology of the kidney, it progresses to explain how diuretics actually work, via symports on the inside of the renal tubules. The different classes of diuretics are characterized, along with their mode of action. The clinical use of diuretics in conditions like congestive cardiac failure and hypertension, as well as some rarer, but clinically important, conditions is then examined. An account is given of the adverse effects of diuretics and how they come about. Common adverse effects like Hypokalaemia and Hyponatraemia are examined in some detail, and other electrolyte disturbances like hypomagnesaemia also gain a mention. Diuretic use in chronic kidney disease is examined and new guidelines that have been introduced are presented. A section on diuretic abuse is included as this is becoming an all too common clinical scenario, and the sometimes tragic consequences of this abuse are emphasized. Diuretics also find a role in the diagnosis of forms of renal tubular acidosis and this role is explored.

KEYWORDS: Diuretics, CHF, Disease, MOA, Clinical

INTRODUCTION:

They seek to boost the excretion of water and electrolytes from the urine, such as sodium and potassium. Recently, these modulators have found to be beneficial in cases where other states of oedema are not present. The use of diuretics to treat a number of illnesses such as diabetic eye disease, hyposencephaly (a disorder caused by too much acid in the body), hyerdineuroidrosis (excessive urinary formation), and renal tubular acidosis (an excessive kidney excretion of acid) has also been prevalent among drug abusers. A diuretic formulation can be difficult because many drugs have trade names. Diuretic treatment is checked. Sodium and water excretion diuretics (drugs that decrease the amount of sodium filtered by the kidney) can cause water and electrolyte loss 1 Altered oxygen capacity is also known to cause volume overload conditions such as heart failure and cirrhosis of the liver The pharmacokinetic and pharmacodynamic properties of various types of diuretics are often different; as a result, recommendations for their usage vary. to become evident when playing back on a recording unit, an effect occurs several times; played back on a turntable disc, it can only occur once dysfunction (either volume or hypertension in those with advanced chronic kidney disease These medications are prescribed for patients with normal blood pressure as a baseline as a first-line treatment option Potassium-

sparing diuretics are also are used to help with hypertension, or for elevated levels of aldosterone in patients with potassium deficiency.) Carbonicase inhibitors are mainly used to treat elevated levels of aqueous fluid, such as glaucomaoucoma This isthe first line of treatment for those with cerebral edoema and can lead to many problems with electrolyte and acid-base balance disturbances

DRUG CLASSES:



FIG 1: DRUG CLASSES OF DIEURETICS

PRINCIPLE OF DIURETICS ACTION

i. All diuretics excluding mannitol and vasopressantagonists operate by inhibiting various sites within the renal tubules to a greater or lesser extent on the sodium reabsorption pathway, causing a gradual rise in the sodium fractional excretion .

ii. Scopolamine, hyoscine (or scopolamine) is a Caribbean-made polydrug commonly used in dreams to treat the euphoria or insomnia that results from highly toxic fish and vegetables, such as shark, sea cucumber, puffer fish, abalone, conch, and banana blossoms

iii. Less than 5% is secreted into the tubular fluid to goal levels

iv. Self-confidence is a state of mind in which a person behaves as though no effort were needed and expects success to come without effort.

v. The secretory mechanism occurs in the proximal kidney tubule IV.

vi. These drugs, which are primarily bicarbonate and citrate cations, are excreted by transporters that operate with organic anions (such as aldosterone and acetate) found in the first section of the nephron (which is next to the collecting duct.)

vii. These substances (amilides and triamethylamines) are synthesised in the proximal part of the kidney tubule through organic cation transporters (pathways for transport of organic base).

viii. Higher doses are needed to meet therapeutic actions in the insufficiency.

ix. Since spironolone and erenone activate transporter proteins in the nephron, their target areas are located outside the tubular cell but indirectly, they have the effect of inhibiting tubular resorptive pumps on the side of the peritubular membrane

x. The two mannitol and vasopressin receptor antagonists reduce water reabsorption and water retention, respectively.

MECHANISM OF DIURETIC ACTION:

Understanding how a specific diuretic impacts a patient's therapeutic needs and side effects is vital for their clinical use. Stopflow, micropuncture, autoradiography, and perfusion cannot be used in man since the kidneys in humans have a different function. instead using indirect means, such as dilution and concentration techniques will be needed



FIG 2: M.O.A OF DIURECTICS

the red blood enters the glomerular capillaries inside the medulla (outer zone of the kidney). Capillary permeability is very high, these glomeruli depend on water and electrolytes to do their job. hydrostatic capillary filter forces water and electrolytes into Bowman's reservoir (PCT). a (termed filtration fraction). PCCT, which is located inside the filtrate (urine), facilitates sodium and bicarbonate movement through the cortex and through the interstium. With water filtration, 65-70% of the purified sodium is excreted from the body's system (this is termed sodium reabsorption). This sodium is absorbed through reabsorption, meaning each sodium reabsorption molecule contains a water molecule. when the tubule reaches the cortex, the tubule becomes constricted and creates an ascending loop (TAL) that connects to the glomerulus.

USES OF DIURETIC IN SOME DISEASES

USES OF DIURETICS IN CHF:

The single greatest cause of illness among the elderly Americans is heart failure. More than one million people every year, approximately, are placed in the hospital as a result of recreational marijuana use. In the year after discharge, 50% of patients with heart failure are readmitted to hospitals within 6 months and between 30% and 30 months, and half of those who are admitted to the hospital within 1 year will die A large number of clinical trials have all but failed to find a successful treatment for the complications of acute heart failure. Over 90% of Acute Cardiac Failure (ADH) patients are given intravenous diuretics, but 30% will respond to diuretic treatment Many of these patients had symptoms including difficulty breathing (79%) and wheezing (65%), as well as the findings of pulmonary rales (67%) and peripheral edoema (66%).

Known as the first-line therapy for people with edoema due to congestive heart failure with constipation compared to placebos, the findings in patients with heart failure showed a mortality reduction (3 trials, 202 patients) and no effect on those with heart disease (2 trials) It was shown in 4 clinical trials (169 people) that the use of diuretics increased the ability of patients with chronic heart failure to exercise. There has also been a significant body of scientific evidence found to support the validity of the value of diuretics. In a randomised controlled trial conducted on patients with advanced heart failure and fluid retention, it was found that diuretics increased renal function while having less toxicity. More significant health issues included renal and heart failure, as well as gastrointestinal bleeding and thrombocytopenia.



FIG 3: MOA OF DIURECTICS IN CHF

thiazide diuretic. It is important to note, however, that loop diuretics (e.g., furosemide, torsemide, or bumetanide) are the mainstay of heart failure care. the slowing of loop diuretic absorption can lead to severe heart failure Thus, peak response occurs at about 4 hours after the dose is given Furosemide has absorption that can vary between 10% and 100% while the others have about 100% absorption potential The literature shows that the 1/3 to 1/4 natriuretic response occurs in patients suffering from heart failure (New York Heart Association (NY) class II or III). Easing up on the dosage at timed intervals can do the trick. However, increasing the dosage greatly has no effect on the answer dose-response curve was used Furosemide can be initiated at a dosage of 20mg and advanced to 40mg per patient's indication. The regular dose of fusidobaylimide for patients with normal filtration range is 600mg. If the maximum dosage has already been administered, increasing the dose to two or three times a day is recommended. There is a dosage range from 2 to 3 mg daily (initial dose: 0.5 mg, maximum: 10 mg) to 20 mg daily (initial 5 mg, maximum 200 mg) It has been found that torsemide and bumide are superior to fosinject for heart failure in clinical trials [6,8,9,10,31–33] Efforts to minimise dyspnea and fatigue contributed to increased weight loss A significant decrease in readmission rate and all-cause mortality was seen in patients treated with this plan, too. as explained above, furosemide's lower bioavailability explains these findings Additionally, furosemide has a half-life of just 12 hours, while bumide has a half-life of over 60 hours and toride has a half-that of both 12 and 60 hours. In advanced heart failure, they are believed to be more effective when given intravascularly (directly into the blood stream). Creative: Initially, the dose is at 20 to 40mg or 2.5 times the oral dose; progressively, the dosage is increased until effective. The therapy can be increased at 2-hour intervals, up to the full tolerable dosage levels. Semide usually use IV doses of 160 to 200 mg of furosemide and 20 to 40 mg of torsemide, as well as

subcutaneous doses of 1 to 2 mg of bumetanide. Full bolus doses of 160 to 200mg of furosemide, 100 to 200mg of bumetanide (total), or 4 to 8mg of bumetanide are advised in patients with renal dysfunction.

USES OF DIURETICS IN CIRRHOSIS WITH ASCITES:

It is normally recommended that people limit their sodium intake to between 88mmsol (2000mg of sodium per day) and 128msol (4000mg per day). In one hand, this is one of the second-line therapies; on the other, complete abstinence from drinking is the traditional method of care. It is considered the most appropriate diuretic for those with ascites and edoema to begin with 50mg. Three or four days of time allows for the half-life of the medication to be prolonged. It is often necessary to titrate up to 400mg a day. On the other hand, this can cause gynecomia Using spironolone, on its own, was as strong as when paired with fosfamide showed better results You can use amide at a dosage of 5mg every other day, and raise to 20mg a day. Nevertheless, it does not perform as well as spironolamide.

If an ineffective response is found to be present after measurement of blood pressure, a loop diuretic is administered. A dosage between 40mg and 160mg per day can be prescribed depending on the patient's renal condition. If the patient does not respond after three days, the loop diuretic will be withdrawn and a thiazide diuretic will be substituted. Moderate doses should be given more regularly in patients with renal insufficiency Drugs such as spironolone and thiazides should be considered if notable results are not obtained. We should ask the patient to limit their dietary salt intake.



FIG 4: MOA OF DIURECTIC IN CIRRHOSIS WITH ASCITES

It was proven that furosemide and spironolone had an effect on these diuretics. This group of patients (those with high renin and aldosterone) did not respond to the furosemide treatment, but responded to the medications (the spironapthiolines) with a dose of 300mg per day of aldosterone. With respect to FUROSEMIDE, the long acting fosfamide yielded more urine. the findings obtained in a clinical research over 70 days using the diuretic, Torsemide, were similar in the tests done on water treatment When the octreotide (a blocker of a variety of angiotens) was administered along with a diuretics, it inhibited both the portal and the entire reninangiogenic system, thereby enhancing systemic and hemodynamic work of the renal vessels. in patients who had a serum albumin concentration less than 3.5 g/dL, and, as a result, administered human albumin in the future Our

reported results were on how much human albumin our patient received, instead of diuretics [the dosage] A drop in the concentration of plasma renin was seen in patients treated with diuretic/albumin supplementation.

USES OF DIURETICS IN NEPHROTIC SYNDROME :

when proteinuria, edoema, hyperlipidemia, and hypoalbuminemia are present 3 out of 100,000 adults in the population will experience nephrotic syndrome over the course of a year Other than keeping the condition under control, treating nephrotic syndrome involves minimising proteinuria and avoiding kidney damage. in order to treat hyponatremia, it is important to achieve a negative sodium balance patients are asked to keep their salt consumption (100mmol/day, 3g/day) and start diuretics. It is best treated with diures to maintain electrolyte balance, hemoconcentration should be avoided, and acute renal failure should be anticipated (through progressive removal of edoema with the minimum of vigorous activity), which may lead to thrombosis due to microangiopathy, so that further deterioration can be prevented. since albumin outdiffuses do not permeate the extracellular compartment Combination of albumin and diuretic supplementation may be required to produce adequate loop diuretic levels. An intravenous infusion of 25 mg of furosemide and an intravenous infusion of 25 g of albumin can help the cause diuresis. Combination therapy has no effect on furosemide tubular secretion. however, the usefulness of this information may be limited in patients with albumin concentrations of less than two grammes per deciliter Consequently, therefore, it can be theorised that a mixture of treatments may be advantageous in such patients In addition, since creatinine clearance is decreased, greater amounts of the unbound drug are needed to be effective.



FIG 5: MOA OF DIURECTIC IN NEPHROTIC SYNDROME

furosemide was shown to be more effective when used in combination with albumin in an RCT;the research also demonstrated that coadministration of furosemide with albumin improved urine production and excretion A meta-analysis showed that just eight hours of intravenous use raised the levels of albumin levels in patients with hypoalbuminemia significantly. For the next 24 hours, nothing important occurred. diuretic resistance, and albumin use should be reserved for patients with serious hypoalbuminemia getting the active component of the medication to the target cells is a difficulty. The ceiling dose is 160 to 200mg furosemide administered intravenously, known as bumetanide, or tosylated bumate. Maximum effect results can be achieved with a 20% of the filtered sodium, but this should be borne in mind when treating patients.

DIURECTIC ABUSE

Sadly, individuals can take it upon themselves to take diuretics inappropriately, in situations where no real clinical indication exists. Usually associated with an eating disorder (anorexia nervosa or bulimia), the hypokalaemia which can develop may prove fatal. Diuretic abuse is also encountered in sport and diuretics have been included on The World Anti-Doping Agency's (WADA) list of prohibited substances. The use of diuretics is banned both in and out of competition and diuretics are routinely screened for by antidoping laboratories.

DIURECTICS IN DIAGNOSIS

Diuretics are most often regarded as therapeutic agents, but furosemide has found a particular role in the diagnosis of distal renal tubular acidosis (RTA), also known as type I RTA. The furosemide- fludrocortisone test offers an alternative to the ammonium chloride urinary acidification test and is quicker to perform, as well as being a more palatable approach to test urinary acidification. One of the inherent problems with the ammonium chloride loading test is that it very often causes vomiting such that the test has to be abandoned. In the report by Walsh *et al*., none of the subjects experienced adverse effects and the simultaneous administration of furosemide and the mineralocorticoid fludrocortisone was well tolerated. The authors reasoned that the furosemide increases distal tubule sodium delivery and the consequent enhancement of distal sodium absorption increases the lumen-negative transepithelial voltage, thereby indirectly stimulating proton secretion. The fludrocortisone given simultaneously enhances both principal cell sodium reabsorption and, because it increases the activity of the H^+-ATPase, α-intercalated cell hydrogen ion secretion. The combination, they proposed, should provide sufficient and consistent stimulus to elucidate an acidification defect in type I RTA, without recourse to the use of ammonium chloride which causes a systemic acid load to be excreted.

FUTURE PROSPECTS

New class of diuretics has recently been discovered and provides an exciting challenge for medical science. They are called AQP modulators, and are likely to be commercially exploited since a patent application for the first in its class, AqB013, has recently been submitted. Physiologists had long pondered the existence of ‘gates’ that could allow rapid reabsorption of water by renal tubular cells. Diffusion will only permit a mere trickle of water across what is effectively a hydrophobic barrier – the lipid bilayer of the cell membrane first proposed in 1935 as the Danielli–Davson model.

With the characterization in the early 1990s of water channels called AQPs came the explanation of how water can pass through a membrane at around the rate of three billion water molecules per second per AQP channel. Several members of the AQP family also allow glycerol and urea permeability. AQP1 predominates in the proximal tubule and descending thin limb of the loop of Henlé, while AQP2 is present in the principal cells of the collecting duct, where, in response to vasopressin, it shuttles between intracellular vesicles and the apical membrane. Increased activity of AQP2 is a contributory factor in the pathophysiology of cirrhosis, heart failure and nephrotic syndrome (all conditions where diuretics form part of the treatment/management strategy). Mutations in the AQP2 gene cause nephrogenic diabetes insipidus. Mouse knockout models have been developed to explore the possibilities of modulating AQP function and expression. Verkmann's review concludes that mouse phenotype data suggest that modulators of AQP expression/function may have wide-ranging clinical applications such as diuretics and in the treatment of cerebral oedema, epilepsy, glaucoma, obesity and cancer.

REFERENCES

1. R. W. Schrier, "Use of diuretics in heart failure and cirrhosis," *Seminars in Nephrology*, vol. 31, no. 6, pp. 503–512, 2011.
2. A. Doucet, G. Favre, and G. Deschênes, "Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications," *Pediatric Nephrology*, vol. 22, no. 12, pp. 1983–1990, 2007.
3. N. Perico and G. Remuzzi, "Edema of the nephrotic syndrome: the role of the atrial peptide system," *American Journal of Kidney Diseases*, vol. 22, no. 3, pp. 355–366, 1993.
4. R. W. Schrier, A. K. Gurevich, and M. A. Cadnapaphornchai, "Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis," *Seminars in Nephrology*, vol. 21, no. 2, pp. 157–172, 2001.
5. R. W. Schrier and R. G. Fassett, "Pathogenesis of sodium and water retention in cardiac failure," *Renal Failure*, vol. 20, no. 6, pp. 773–781, 1998.
6. R. W. Schrier, "Water and sodium retention in edematous disorders: role of vasopressin and aldosterone," *The American Journal of Medicine*, vol. 119, no. 7, supplement 1, pp. S47–S53, 2006.
7. G. Deschênes, V. Guigonis, and A. Doucet, "Molecular mechanism of edema formation in nephrotic syndrome," *Archives de Pediatrie*, vol. 11, no. 9, pp. 1084–1094, 2004.
8. P. Svenningsen, H. Andersen, L. H. Nielsen, and B. L. Jensen, "Urinary serine proteases and activation of ENaC in kidney—implications for physiological renal salt handling and hypertensive disorders with albuminuria," *Pflugers Archiv*, vol. 467, no. 3, pp. 531–542, 2014.
9. E. C. Siddall and J. Radhakrishnan, "The pathophysiology of edema formation in the nephrotic syndrome," *Kidney International*, vol. 82, no. 6, pp. 635–642, 2012.
10. A. C. Guyton, "The microcirculation and the lymphatic system," i*n Textbook of Medical Physiology*, chapter 16, Saunders, Philadelphia, Pa, USA, 8th edition, 1991.
11. D. C. Brater, "Update in diuretic therapy: clinical pharmacology," *Seminars in Nephrology*, vol. 31, no. 6, pp. 483–494, 2011.
12. D. C. Brater, "Diuretic therapy," *The New England Journal of Medicine*, vol. 339, no. 6, pp. 387–395, 1998.
13. D. H. Ellison, "Diuretic drugs and the treatment of edema: from clinic to bench and back again," *American Journal of Kidney Diseases*, vol. 23, no. 5, pp. 623–643, 1994.
14. K. Besseghir and B. Rennick, "Renal tubule transport and electrolyte effects of amiloride in the chicken," *Journal of Pharmacology and Experimental Therapeutics*, vol. 219, no. 2, pp. 435–441, 1981.
15. S. T. Kau, "Handling of triamterene by the isolated perfused rat kidney," *Journal of Pharmacology and Experimental Therapeutics*, vol. 206, no. 3, pp. 701–709, 1978.
16. D. Lloyd-Jones, R. Adams, M. Carnethon et al., "Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee," *Circulation*, vol. 119, no. 3, pp. 480–486, 2009.
17. S. A. Hunt, W. T. Abraham, M. H. Chin et al., "2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation," *Journal of the American College of Cardiology*, vol. 53, no. 15, pp. e1–e90, 2009.

18. G. M. Felker, P. S. Pang, K. F. Adams et al., "Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward," *Circulation: Heart Failure*, vol. 3, no. 2, pp. 314–325, 2010.

19. M. Gheorghiade and G. Filippatos, "Reassessing treatment of acute heart failure syndromes: the ADHERE Registry," *European Heart Journal*, vol. 7, supplement, pp. B13–B19, 2005.

20. R. F. Faris, M. Flather, H. Purcell, P. A. Poole-Wilson, and A. J. Coats, "Diuretics for heart failure," *Cochrane Database of Systematic Reviews*, no. 2, Article ID CD003838, 2012.

21. B. A. Bart, S. R. Goldsmith, K. L. Lee et al., "Ultrafiltration in decompensated heart failure with cardiorenal syndrome," *The New England Journal of Medicine*, vol. 367, no. 24, pp. 2296–2304, 2012.

22. D. Shchekochikhin, F. Al Ammary, J. Lindenfeld, and R. Schrier, "Role of diuretics and ultrafiltration in congestive heart failure," *Pharmaceuticals*, vol. 6, no. 7, pp. 851–866, 2013.

23. M. R. Vasko, D. B. Cartwright, J. P. Knochel, J. V. Nixon, and D. C. Brater, "Furosemide absorption altered in decompensated congestive heart failure," *Annals of Internal Medicine*, vol. 102, no. 3, pp. 314–318, 1985.

24. D. C. Brater, B. Day, A. Burdette, and S. Anderson, "Bumetanide and furosemide in heart failure," *Kidney International*, vol. 26, no. 2, pp. 183–189, 1984.

25. S. A. Hunt, W. T. Abraham, M. H. Chin et al., "2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation," *Journal of the American College of Cardiology*, vol. 53, no. 15, pp. e1–e90, 2009.

26. K. A. Wargo and W. M. Banta, "A comprehensive review of the loop diuretics: should furosemide be first line?" *Annals of Pharmacotherapy*, vol. 43, no. 11, pp. 1836–1847, 2009.

27. J. J. Dinicolantonio, "Should torsemide be the loop diuretic of choice in systolic heart failure?" *Future Cardiology*, vol. 8, no. 5, pp. 707–728, 2012.

28. M. D. Murray, M. M. Deer, J. A. Ferguson et al., "Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure," *The American Journal of Medicine*, vol. 111, no. 7, pp. 513–520, 2001.

29. J. Cosín and J. Díez, "Torasemide in chronic heart failure: results of the TORIC study," *European Journal of Heart Failure*, vol. 4, no. 4, pp. 507–513, 2002.

30. J. C. Jentzer, T. A. Dewald, and A. F. Hernandez, "Combination of loop diuretics with thiazide-type diuretics in heart failure," *Journal of the American College of Cardiology*, vol. 56, no. 19, pp. 1527–1534, 2010.

31. G. Licata, P. Di Pasquale, G. Parrinello et al., "Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects," *American Heart Journal*, vol. 145, no. 3, pp. 459–466, 2003.

32. J. Santos, R. Planas, A. Pardo et al., "Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety," *Journal of Hepatology*, vol. 39, no. 2, pp. 187–192, 2003.

33. R. P. Hull and D. J. A. Goldsmith, "Nephrotic syndrome in adults," *British Medical Journal*, vol. 336, no. 7654, pp. 1185–1189, 2008.

34. H. Velázquez and F. S. Wright, "Control by drugs of renal potassium handling," *Annual Review of Pharmacology and Toxicology*, vol. 26, pp. 293–309, 1986.

35. D. Siegel, S. B. Hulley, D. M. Black et al., "Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men," *Journal of the American Medical Association*, vol. 267, no. 8, pp. 1083–1089, 1992.

36. D. A. Sica, B. Carter, W. Cushman, and L. Hamm, "Thiazide and loop diuretics," *The Journal of Clinical Hypertension*, vol. 13, no. 9, pp. 639–643, 2011.

37. H. A. Cooper, D. L. Dries, C. E. Davis, Y. L. Shen, and M. J. Domanski, "Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction," *Circulation*, vol. 100, no. 12, pp. 1311–1315, 1999.

38. M. Hafizullah, K. Bangash, and F. Abbas, "Comparative efficacy and tolerability of lasoride and spiromide in congestive cardiac failure," *Journal of Postgraduate Medical Institute (Peshawar, Pakistan)*, vol. 14, no. 1, pp. 36–42, 2011.

39. D. R. Salvador, N. R. Rey, G. C. Ramos, and F. E. Punzalan, "Continuous infusion versus bolus injection of loop diuretics in congestive heart failure," *Cochrane Database of Systematic Reviews*, no. 3, Article ID CD003178, 2005.

40. A. Palazzuoli, M. Pellegrini, B. Franci et al., "Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction," *Internal and Emergency Medicine*, vol. 10, no. 1, pp. 41–49, 2015.

41. M.-Y. Wu, N.-C. Chang, C.-L. Su et al., "Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials," *Journal of Critical Care*, vol. 29, no. 1, pp. 2–9, 2014.